Breast Cancer Female NOS, HER2 Positive Breast Cancer, Inflammatory Breast Cancer, Invasive Ductal Breast Cancer, Mucinous Breast Cancer Stage II, Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III
Conditions
Brief summary
Pharmacologic inhibition of RANKL attenuates the development of mammary carcinoma and inhibits metastatic progression in multiple mouse models. In a retrospective analysis it could be demonstrated that elevated expression of RANK was found in 14.5% of patients overall, with a significant predominance in patients with hormone-receptor-negative disease. Expression of RANK was associated with a higher pathological complete response rate but with a shorter disease-free and overall survival. The ABCSG-18 study showed that adjuvant denosumab reduces clinical fractures, improves bone health, and can be administered without added toxicity. It appears therefore reasonable to test denosumab, a clinically available antibody against RANKL in patients with hormone-receptor-negative primary breast cancer as an adjunct to neoadjuvant chemotherapy for its ability to increase pCR rate and improve outcome in relation to the expression of RANK.
Detailed description
RANK ligand (RANKL), a key factor for bone remodeling and metastasis, is crucial for the development of mouse mammary glands during pregnancy. RANKL functions as a major paracrine effector of the mitogenic action of progesterone in mouse and human mammary epithelium via its receptor RANK and has a role in ovarian hormone-dependent expansion and regenerative potential of mammary stem cells. Pharmacologic inhibition of RANKL attenuates the development of mammary carcinoma and inhibits metastatic progression in multiple mouse models. In a retrospective analysis of 601 patients treated in the GeparTrio study with chemotherapy (TAC) it could be demonstrated that elevated expression of RANK (immunohistochemical score \> 8.5 using the N-1H8 antibody by Amgen) was found in 14.5% of patients overall, with a significant predominance in patients with hormone-receptor-negative disease (33.7% vs 6.4% tumors positive for RANK). Expression of RANK was associated with a higher pathological complete response rate (pCR) (23.0% vs 12.6%) but with a shorter disease-free and overall survival. The ABCSG-18 study showed that adjuvant denosumab reduces clinical fractures, improves bone health, and can be administered without added toxicity. Moreover denosumab improves disease-free survival in postmenopausal woman with hormone receptor positive breast cancer. It appears therefore reasonable to test denosumab, a clinically available antibody against RANKL in patients with hormone-receptor-negative primary breast cancer as an adjunct to neoadjuvant chemotherapy for its ability to increase pCR rate and improve outcome in relation to the expression of RANK.
Interventions
DRUGDenosumab
Denosumab 120 mg every 4 weeks for 6 cycles
DRUGnab-Paclitaxel
nab-paclitaxel 125 mg/m² weekly for 12 weeks or at day 1,8 q22 for 4 cycles (12 weeks)
DRUGEpirubicin
Epirubicin 90 mg/m² every 2 or 3 weeks for 4 times
DRUGCyclophosphamide
Cyclophosphamide 600 mg/m² every 2 or 3 weeks for 4 times
DRUGCarboplatin
Carboplatin AUC 2 weekly in parallel to nab-Paclitaxel
DRUGTrastuzumab
Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles
DRUGPertuzumab
Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles
Sponsors
Amgen
Celgene Corporation
GBG Forschungs GmbH
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy. Fine-needle aspiration from the breast lesion alone is not sufficient. Incisional biopsy or axillary clearance is not allowed. In case of bilateral cancer, the investigator has to decide prospectively which side will be evaluated for the primary endpoint. * Tumor lesion in the breast with a palpable size of 2 cm or a sonographical size of 1 cm in maximum diameter. The lesion has to be measurable in two dimensions, preferably by sonography. In case tumor isn't measurable by sonography, then MRI or mammography is sufficient. In case of inflammatory disease, the extent of inflammation can be used as measurable lesion. * Patients must have stage cT1c - cT4a-d disease. * In patients with multifocal or multicentric breast cancer, the largest lesion should be measured. * Centrally confirmed ER-negative and PR-negative status. Central pathology includes also assessment of HER2, Ki-67, TIL and RANK status on core biopsy. ER/PR negative is defined as ≤1% stained cells and HER2-positive is defined as IHC 3+ or in-situ hybridization (ISH) and according to ASCO-CAP guidelines as of 2013. LPBC (lymphocyte predominant breast cancer) is defined as more than 50% stromal tumour infiltrating lymphocytes. Formalin-fixed, paraffin-embedded (FFPE) breast tissue from core biopsy has therefore to be sent to the GBG central pathology laboratory prior to randomization.
Exclusion criteria
* Patients with stages cT1a, cT1b, or any M1. * Prior chemotherapy for any malignancy. * Prior radiation therapy for breast cancer. * History of disease with influence on bone metabolism, such as osteoporosis, Paget's disease of bone, primary hyperparathyroidism requiring treatment at the time of randomization or considered likely to become necessary within the subsequent six months. * Use of bisphosphonates or denosumab within the past 1 year. * Significant dental/oral disease, including prior history or current evidence of osteonecrosis/ osteomyelitis of the jaw, active dental or jaw condition which requires oral surgery, non-healed dental/oral surgery, planned invasive dental procedure for the course of the study. * Previous malignant disease being disease-free for less than 5 years (except CIS of the cervix and non-melanomatous skin cancer). * Known or suspected congestive heart failure (\>NYHA I) and / or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, uncontrolled or poorly controlled arterial hypertension (i.e. BP \>140 / 90 mm Hg under treatment with two antihypertensive drugs), rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease. * Currently active infection. * Incomplete wound healing. * Definite contraindications for the use of corticosteroids.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pcR rates of neoadjuvant treatment with or without denosumab in addition to nab-paclitaxel and EC. | 24 weeks |
| pcR (ypT0 ypN0) rates of nab-Paclitaxel weekly for 12 weeks or 2 of 3 weeks for 12 weeks | 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| To test for interaction of denosumab treatment with RANK expression. | 24 weeks |
| To assess the pCR rates per arm for both randomizations separately for TNBC and HR-/HER2+ tumors. | 24 weeks |
Countries
Germany
Outcome results
None listed